ABSTRACT
Malaria and HIV/AIDS have a wide geographical overlap in several tropical
regions. This makes co-infection of the two diseases very common. Due to
enhanced global coverage of antiretroviral drugs (ARVs), HIV/AIDS patients
are under ARVs including protease inhibitors (PIs). Just like HIV, malaria
parasite also depend on proteases in their life cycle. Therefore, PIs against
HIV could offer some level of antimalarial activity by targeting the parasite
proteases. This study sought to investigate the antimalarial activity of HIV PIs
and their interaction with antimalarial drugs in mice models. The effective
dose 50 (ED50) for three PIs ritonavir, saquinavir and nelfinavir and the
antimalarial drugs artemether and lumefantrine was assessed using Peter’s 4-
day suppressive test against Plasmodium berghei. Chemosupression was
assessed on day 7, 10 and 13 after antimalarial and PIs treatment. Prophylactic
activity was assessed 2h, 3h and 5h post drug administration (pda). Interaction
of PIs with artemether and lumefantrine was also determined using the
suppression test. The ED50 was calculated using regression equation in
statistica software version 12.5. Student’s t-test was used to compare the mean
parasitaemia of the control and treatment groups. Drug interaction data was
analysed using one-way ANOVA and Tukey’s test. The analysis were done
using SPSS version 22. Artemether, lumefantrine, ritonavir, saquinavir and
nelfinavir had ED50 values of 1.04, 1.67, 3.84, 4.86 and 4.92 mg/kg,
respectively. Antimalarial drugs had significant (p < 0.05) chemosuppression
activity throughout and lumefantrine was more effective (67.7% - 84.5%) than
artemether (24.5% - 73.6%). For PIs, on day 10 pi, ritonavir had significant (p
< 0.05) antimalarial activity (24.5%) as compared to saquinavir (13.3%) and
nelfinavir (9.8%). For prophylactic activity ritonavir and nelfinavir had
significant (p < 0.05) parasitaemia suppression at 3h pda while for saquinavir
it was 5h pda. Drug interaction studies indicated that drug combination were
more effective than stand-alone but the suppression was only significant (p
MBURU, D (2021). Prophylactic Activity Of Hiv-Protease Inhibitors Against Malaria And Their Interaction With Antimalarial In Male Mice. Afribary. Retrieved from https://afribary.com/works/prophylactic-activity-of-hiv-protease-inhibitors-against-malaria-and-their-interaction-with-antimalarial-in-male-mice
MBURU, DOMINIC "Prophylactic Activity Of Hiv-Protease Inhibitors Against Malaria And Their Interaction With Antimalarial In Male Mice" Afribary. Afribary, 26 May. 2021, https://afribary.com/works/prophylactic-activity-of-hiv-protease-inhibitors-against-malaria-and-their-interaction-with-antimalarial-in-male-mice. Accessed 29 Nov. 2024.
MBURU, DOMINIC . "Prophylactic Activity Of Hiv-Protease Inhibitors Against Malaria And Their Interaction With Antimalarial In Male Mice". Afribary, Afribary, 26 May. 2021. Web. 29 Nov. 2024. < https://afribary.com/works/prophylactic-activity-of-hiv-protease-inhibitors-against-malaria-and-their-interaction-with-antimalarial-in-male-mice >.
MBURU, DOMINIC . "Prophylactic Activity Of Hiv-Protease Inhibitors Against Malaria And Their Interaction With Antimalarial In Male Mice" Afribary (2021). Accessed November 29, 2024. https://afribary.com/works/prophylactic-activity-of-hiv-protease-inhibitors-against-malaria-and-their-interaction-with-antimalarial-in-male-mice